Extended Data Fig. 5: Expression of ISGs in patient tumor biopsies.
From: Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Log2 fold change (on- versus pre-treatment) of expression of top 50 genes from pEpiTd19 ISG program in tumor epithelial cells of patients with PFS > 6 months and < 6 months.
